CAMBRIDGE, Mass.--(EON: Enhanced Online News)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA), a rare cancer-focused innovative biotechnology company, today announced that it will present at the 35th Annual J.P. Morgan Healthcare Conference. Paris Panayiotopoulos, president and chief executive officer, will provide an overview of the Company’s business on Monday, January 9, 2017 at 4:30 p.m. (PT).
The ARIAD presentation will be webcast live and can be accessed by visiting the investor relations section of the Company’s website at http://www.ariad.com/investor. A replay of the presentation will also be available and archived on the site for three weeks.
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).